AU2007316588B2 - Oral dosage form comprising tri-substituted glycerol compounds - Google Patents

Oral dosage form comprising tri-substituted glycerol compounds Download PDF

Info

Publication number
AU2007316588B2
AU2007316588B2 AU2007316588A AU2007316588A AU2007316588B2 AU 2007316588 B2 AU2007316588 B2 AU 2007316588B2 AU 2007316588 A AU2007316588 A AU 2007316588A AU 2007316588 A AU2007316588 A AU 2007316588A AU 2007316588 B2 AU2007316588 B2 AU 2007316588B2
Authority
AU
Australia
Prior art keywords
dosage form
solid dosage
pharmaceutical solid
tri
form according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007316588A
Other languages
English (en)
Other versions
AU2007316588A1 (en
Inventor
Wolfgang Richter
Lutz Weber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellprotect Patent AG
Original Assignee
Cellprotect Patent AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellprotect Patent AG filed Critical Cellprotect Patent AG
Publication of AU2007316588A1 publication Critical patent/AU2007316588A1/en
Application granted granted Critical
Publication of AU2007316588B2 publication Critical patent/AU2007316588B2/en
Assigned to CELLPROTECT PATENT AG reassignment CELLPROTECT PATENT AG Request for Assignment Assignors: ALPHAPTOSE GMBH
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2007316588A 2006-11-10 2007-11-09 Oral dosage form comprising tri-substituted glycerol compounds Ceased AU2007316588B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85815706P 2006-11-10 2006-11-10
US60/858,157 2006-11-10
PCT/EP2007/062180 WO2008055996A1 (en) 2006-11-10 2007-11-09 Oral dosage form comprising tri-substituted glycerol compounds

Publications (2)

Publication Number Publication Date
AU2007316588A1 AU2007316588A1 (en) 2008-05-15
AU2007316588B2 true AU2007316588B2 (en) 2013-11-21

Family

ID=39092201

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007316588A Ceased AU2007316588B2 (en) 2006-11-10 2007-11-09 Oral dosage form comprising tri-substituted glycerol compounds

Country Status (11)

Country Link
US (2) US20110110984A1 (enExample)
EP (1) EP2091520B1 (enExample)
JP (1) JP5352466B2 (enExample)
CN (2) CN101610758A (enExample)
AT (1) ATE546133T1 (enExample)
AU (1) AU2007316588B2 (enExample)
CA (1) CA2668919C (enExample)
DK (1) DK2091520T3 (enExample)
ES (1) ES2382756T3 (enExample)
RU (1) RU2009121838A (enExample)
WO (1) WO2008055996A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1745788A1 (de) * 2005-07-22 2007-01-24 KTB Tumorforschungsgesellschaft mbH Acylglycerophospholipide zur Behandlung von Krebs und Tumorkachexie
US20100136029A1 (en) * 2006-12-20 2010-06-03 Universitatsklinikum Hamburg-Eppendorf Use of Tri-Substituted Glycerol Compounds for the Treatment of Hematological Malignancies
EP1952803A1 (en) * 2007-01-23 2008-08-06 KTB-Tumorforschungs GmbH Solid pharmaceutical dosage form containing hydrogenated phospholipids

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266564A (en) * 1989-06-02 1993-11-30 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E. V. Method for treating certain autoimmune diseases
US6514519B1 (en) * 1998-05-19 2003-02-04 Med-Mark Pharma Gmbh Edelfosin for the treatment of brain tumors
US6583127B1 (en) * 1998-12-21 2003-06-24 Inkeysa. Sa Use of etherlysophospholipids as antiinflammatory agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2619686C2 (de) 1976-05-04 1986-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Verwendung eines Lysolecithins zur Tumorbehandlung
DE3530767A1 (de) * 1985-08-28 1987-03-12 Max Planck Gesellschaft Mittel gegen multiple sklerose
DE3827974A1 (de) * 1988-08-18 1990-02-22 Boehringer Mannheim Gmbh Kombinationspraeparate von proteinkinase-c-inhibitoren mit lipiden, lipid-analoga, cytostatica oder inhibitoren von phospholipasen
DE4000084A1 (de) 1990-01-03 1991-07-04 Medmark Pharma Gmbh Intravenoes applizierbare pharmazeutische zubereitung von et18-och(pfeil abwaerts)3(pfeil abwaerts)
AU1827799A (en) * 1997-12-15 1999-07-05 Axia Therapeutics, Inc. Oral delivery formulation
DE19829448A1 (de) 1998-07-01 2000-10-12 Medmark Pharma Gmbh 1-Octadecyl-2-methyl-sn-glycero-3-phosphocholin (ET180CH3) zur Behandlung von humanen Mammakarzinomen
CN1688291A (zh) * 2002-02-01 2005-10-26 辉瑞产品公司 含有固体药物分散体的即刻释放剂型
US7230012B2 (en) * 2002-11-14 2007-06-12 Celgene Corporation Pharmaceutical compositions and dosage forms of thalidomide

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266564A (en) * 1989-06-02 1993-11-30 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E. V. Method for treating certain autoimmune diseases
US6514519B1 (en) * 1998-05-19 2003-02-04 Med-Mark Pharma Gmbh Edelfosin for the treatment of brain tumors
US6583127B1 (en) * 1998-12-21 2003-06-24 Inkeysa. Sa Use of etherlysophospholipids as antiinflammatory agents

Also Published As

Publication number Publication date
WO2008055996A1 (en) 2008-05-15
CN103816127A (zh) 2014-05-28
DK2091520T3 (da) 2012-06-18
CA2668919A1 (en) 2008-05-15
US20110110984A1 (en) 2011-05-12
JP2010509293A (ja) 2010-03-25
US20170157150A1 (en) 2017-06-08
EP2091520B1 (en) 2012-02-22
EP2091520A1 (en) 2009-08-26
RU2009121838A (ru) 2010-12-20
ATE546133T1 (de) 2012-03-15
JP5352466B2 (ja) 2013-11-27
ES2382756T3 (es) 2012-06-13
CN101610758A (zh) 2009-12-23
CA2668919C (en) 2015-11-03
AU2007316588A1 (en) 2008-05-15

Similar Documents

Publication Publication Date Title
JP6357687B2 (ja) ラコサミドの１日１回投与用製剤
FI85439C (fi) Foerfarande foer framstaellning av ett laekemedelspreparat som doseras oralt och moejliggoer en kontrollerad frigoerelse.
JP3954117B2 (ja) 有効物質を徐々に遊離する、トラマドール塩含有薬剤
KR101442862B1 (ko) 만니톨 또는 유당을 함유하는 고형 제제
CA2182004C (en) Film coated tablet of paracetamol and domperidone
JP2020535158A (ja) ニラパリブ処方物
EP2468261A1 (en) Formulation of lacosamide
TW200539902A (en) Oral pharmaceutical compositions of timed-release particles and tablets quickly disintegrable in the oral cavity containing compositions thereof
JP2006528237A (ja) バレニクリンの医薬組成物
MX2010008711A (es) Composiciones farmaceuticas de entacapona, levopoda y carbidopa, con biodisponibilidad mejorada.
HUE027664T2 (en) Nalbuphine-based formulations and uses thereof
JP2005508901A (ja) 活性成分を徐放する剤形
KR20100099113A (ko) 만니톨 및/또는 미세결정질 셀룰로스를 포함하는 지보텐탄 조성물
EP3013327B1 (en) Pharmaceutical capsule composite formulation comprising tadalafil and tamsulosin
KR102090440B1 (ko) 신규한 (트리메톡시페닐아미노)피리미디닐 제형
US20170157150A1 (en) Oral dosage form comprising tri-substituted glycerol compounds
EP2175855B1 (en) Stable pharmaceutical composition of a water-soluble vinorelbine salt
WO2017029225A1 (en) Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
EP1962810A2 (en) Pharmaceutical compositions of short-acting hypnotic agents in modified-release forms and the procedures to prepare the mentioned formulations
WO2014167439A1 (en) Modified release pharmaceutical compositions of topiramate or salts thereof
KR20090082608A (ko) 이부딜라스트를 유효성분으로 함유하는 장용서방형약제학적 조성물 및 이의 제조방법
CN111759850A (zh) 草酸替诺福韦的药物组合物
Bose et al. INTERNATIONAL RESEARCH JOURNAL OF PHARMACY
CZ20002675A3 (cs) Tiagabinové prostředky s prodlouženým uvolňováním se sníženými vedlejšími účinky
HK1144662A (zh) 包含水溶性长春瑞滨盐的稳定的药物组合物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: CELLPROTECT PATENT AG

Free format text: FORMER OWNER WAS: ALPHAPTOSE GMBH

MK14 Patent ceased section 143(a) (annual fees not paid) or expired